{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009898","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.849041+00:00","generated_at":"2026-06-04T19:38:29.772370+00:00","sec_items":["1.01","3.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PAVmed subsidiary Lucid Diagnostics raises $12.5M via Series B Preferred Stock offering and exchange","bullets":["Lucid Diagnostics sold 12,495 shares of Series B Convertible Preferred at $1,000/share, raising $12.495M.","Investors exchanged 13,625 Series A and 10,670 Series A-1 shares for 31,790 Series B shares.","Closing on March 13, 2024; Lucid filed certificate of designation for Series B and amendment for Series A-1.","Registration rights agreement filed for resale of common stock issuable upon conversion of Series B Preferred."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009898","json":"https://secwatch.observer/filing/0001493152-24-009898.json","markdown":"https://secwatch.observer/filing/0001493152-24-009898.md","text":"https://secwatch.observer/filing/0001493152-24-009898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/0001493152-24-009898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:38:29.772370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"009b90251b8c406f593d7a57d33dad46e3f57ccb","claim":"PAVmed Inc. entered into Registration Rights Agreement with Series B Investors (effective 2024-03-13).","evidence_excerpt":"Lucid Diagnostics and the Series B Investors also executed a registration rights agreement (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable pursuant to the Series B Preferred Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/0001493152-24-009898-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Series B Investors"},{"label":"Effective","value":"2024-03-13"}],"fact_type":"material_agreement"},{"claim_id":"aea50d1e1c257f1265d114b25fb7958bb73b0b4c","claim":"PAVmed Inc. entered into Series B Subscription Agreement with certain accredited investors valued at 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value (effective 2024-03-13).","evidence_excerpt":"On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/0001493152-24-009898-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value"},{"label":"Effective","value":"2024-03-13"}],"fact_type":"material_agreement"},{"claim_id":"f4184acd9a214d332427db419e7f33e36d2ba1eb","claim":"PAVmed Inc. entered into Exchange Agreement with certain accredited investors valued at 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (effective 2024-03-13).","evidence_excerpt":"On March 13, 2024, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), entered into subscription agreements (each, a “ Series B Subscription Agreement ”) and exchange agreements (each, an “ Exchange Agreement ”) with certain accredited investors (collectively, the “ Series B Investors ”), which agreements provided for (i) the sale to the Series B Investors of 12,495 shares of Lucid Diagnostics’ newly designated Series B Convertible Preferred Stock, par value $0.001 per share (the “ Series B Preferred Stock ”), at a purchase price of $1,000 per share, and (ii) the exchange by the Series B Investors of 13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), and 10,670 shares of Lucid Diagnostics’ Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series A-1 Preferred Stock ”), held by them for 31,790 shares of Series B Prefe","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315224009898/0001493152-24-009898-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"13,625 shares of Lucid Diagnostics’ Series A Convertible Preferred Stock, par value $0.001 per share"},{"label":"Effective","value":"2024-03-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}